Health care counsel with a focus on 340B program and pharmacy-related issues

Michael French works with a variety of health care clients, including pharmacies, drug wholesalers, pharmacy benefit managers (PBM), hospitals, FQHCs, RHCs, post-acute care facilities, clinical laboratories and complex health care systems. He advises his clients on regulatory, legal and operational issues relating to:

• 340B program compliance and optimization
• Pharmacy regulatory compliance
• Hospital provider-based department conversions
• Medicare and Medicaid billing and reimbursement
• Telehealth
• Health care transactions

Although Michael’s practice is wide ranging, he maintains a particular focus on 340B drug pricing program issues. Michael has conducted client-facing on-site 340B and pharmacy operational assessments, assisted clients in preparing for Health Resources and Services Administration (HRSA) 340B audits, provided on-site support during audits and assisted with drafting Notice of Disagreements to mitigate and overturn associated government findings.

Leveraging his previous consulting experience, Michael provides usable, practical guidance that accounts for both legal and business considerations. He takes the time to learn the ins and outs of his clients’ operational models and crafts his advice to compliantly further his clients’ goals.

Bar Admissions

• Illinois

Education

• Loyola University Chicago School of Law (J.D., magna cum laude, 2016)
  • Health Law Certificate from the Beazley Institute for Health Law and Policy

• University of Notre Dame (B.A., 2013)

• "340B Drug Pricing Program"
• "340B Program Upheaval: Compliantly Navigating Program Uncertainties While Maximizing Available Benefits"
• "A Program in Upheaval: What to Expect in the 340B Space Moving Forward"
• "Changes to the 340B Program: What Covered Entitles Must Know"
• "Future of 340B: Key Considerations and Optimization Strategies for Small and Rural Hospitals"
• 340B Developments in 2024 – Litigation and Legislation
• 340B Program Changes on the Horizon? Start Planning Now for Potentially Seismic Impact of Upcoming Genesis Decision
• 340B Program Compliance in a Shifting Landscape: What Challenges Do Stakeholders Face?
• Amidst Ongoing Manufacturer Restrictions, 340B Covered Entities and Contract Pharmacies Get Creative
• Brenda Shafer, Michael French and Richard Davis Author Law360 Article on Questions Related to Section 340B Drug Pricing
• California Board of Pharmacy Changes
• CMS Proposal to Make One-Time $9 Billion Lump Sum Payment to 340B-Covered Entity Hospitals
• Continuing Changes in the 340B Space: New Restrictions and Shifting Alliances
• District Court Allows for Expanded Interpretation of Eligible Patient in Impactful 340B Program Ruling
• HRSA Notice Provides Clarity on 340B Child Site Registration Requirements
• New Limitations on Chain Pharmacy Quotas in California
• Rhode Island Pharmacist Drug Administration Expansion
• Supreme Court Decision Maintains Status Quo for Disproportionate Share Percentage Calculation: What Does It Mean for the 340B Program?
• The Current State of 340B and What to Expect in 2023
• UPDATE: U.S. Supreme Court Sides with 340B Hospitals in Significant $1.6 Billion Part B Drug Payment Ruling
• UPDATE: U.S. Supreme Court Sides with 340B Hospitals in Significant $1.6 Billion Part B Drug Payment Ruling
• “Pharmacy 101 and the 340B Program"
• “Pharmacy Law Update”

Seminar

• 2022 Pharmacy Law Symposium
• 2023 Pharmacy Law Symposium
• 2024 Pharmacy Law Symposium
• 340B Outlook from Capitol Hill, Federal Courts, and the States
• 340B Program: What Covered Entities Must Know